Effects of zoledronic acid in adults with osteogenesis imperfecta;Efectos del tratamiento con ácido zoledrónico en pacientes adultos con osteogénesis imperfecta

Endocrinologia y Nutricion

Volumn 57, Issue 6, 2010, Pages 245-250

  De Paz, Sabel Pavón ^a   Bolaños, Paloma Iglesias ^a   Martínez, Maria Durán ^a   Roldán, Juani Olivar ^a   De Armas, Guadalupe Guijarro ^a   García, Jose Ignacio Parra ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Adults; Bone mrneral densty; Osteogenesis imperecta; Zoledrornc acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

ADOLESCENT; ADULT; ARTICLE; FEMALE; HUMAN; MALE; MIDDLE AGED; OSTEOGENESIS IMPERFECTA; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OSTEOGENESIS IMPERFECTA; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79952202566     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2010.03.017     Document Type: Article

References (21)

1. Prockop DJ, Kivirikko KL. Heritable diseases of collagen. N Engl J Med. 1984;311:376-81.
2. Marini JC. Osteogenesis imperfecta: compresive management. Adv Pediatr. 1988;35:391-6.
3. Chevrel G, Meunier PJ. Osteogenesis imperfecta: lifelong management is imperative and feasible. Joint Bone Spine. 2001;68:125-9. (Pubitemid 32275151)
4. Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf D, et al. Effect of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3 year randomized placebo controlled trial. J Bone Miner Res. 2006;21:300-6. (Pubitemid 43265296)
5. Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman K, Fedarko N, et al. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int. 2003;72:103-12. (Pubitemid 36919531)
6. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, et al. Intravenous noredronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18:126-30. (Pubitemid 36008347)
7. Gatti D, Viapiana O, Lippolis L, Braga V, Prizzi R, Rossini M, et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res. 2005;20:1323-6. (Pubitemid 41033515)
8. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-6.
9. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Trvers R. Ciclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-52. (Pubitemid 28455096)
10. Steelman J, Zeitler P. Treatment of sintomatic pediatric osteoporosis with ciclic single day intravenous pamidronate infusion. J Pediatr. 2003;142:417-23. (Pubitemid 36521229)
11. Gandon-Laloum S. Bisphosphonates and osteogenesis imperfecta in chidren. Arch Pediatr. 2009;16:1085-9.
12. Solomon CG. Bisphosphonates and osteoporosis. N Engl J Med. 2002;346:642. (Pubitemid 34815867)
13. Widdler L, Jaeggi KA, Glatt M, Muller K, Bachmann R, Bisping M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium to zoledronic acid. J Med Chem. 2002;45:3721-38. (Pubitemid 34863233)
14. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-20.
15. Doggrell SA. Zolendronate once-yearly increases bone mineral density-implications for osteoporosis. Expert Opin Pharmacother. 2002;3:1007-9. (Pubitemid 34752517)
16. Reid DM, Derogelaer JP, Saag K, Roux C, Lan CS, Reginster JY, et al. Zoledronic acid and risendronate in theprevention and treatment of glucocorticoid induced osteoporosis (HORIZON): a multicentre, double blind double dummy, randomisd, controlled trial. Lancet. 2009;376:1253-63.
17. Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, et al. Intravenous zoledronic acid treatment in talasemiainduced osteoporosis: results of a phase II clinical trial. Ann Hematol. 2006;85:605-9. (Pubitemid 44283081)
18. Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging. 2003;20:175-83. (Pubitemid 36269580)
19. Brown JJ, Zacharin MR. Saffety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endocrinol Metab. 2009;22:55-63.
20. Panigrahi L, Das RR, Sharda S, Marwaha RK, Khandelwal N. Response to zoledronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab. 2010 (Epub ahead of print).
21. Papapetrou PD. Bisphosphonate associated adverse events. Hormones (Athens). 2009;8:96-110.